Diagnosis and quantification of factor VIII inhibitors

Haemophilia

Volumn 16, Issue 102, 2010, Pages 20-24

  Verbruggen, B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Factor VIII inhibitors laboratory assay; Nijmegen Bethesda assay

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; VON WILLEBRAND FACTOR;

ANTIBODY TITER; ARTICLE; BLEEDING; ENZYME ACTIVITY; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INCUBATION TIME; KINETICS; METHODOLOGY; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; TEMPERATURE;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION TESTS; FACTOR VIII; HUMANS; MASS SCREENING; TEMPERATURE; TIME FACTORS;

EID: 77953218098     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01924.x     Document Type: Article

References (27)

1. Collins PW, Hirsch S, Baglin TP. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 2007, 109:1870-7.
2. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002, 8(Suppl. 2):23-9.
3. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007, 109:4648-54.
4. Dazzi F, Tison T, Vianello F. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996, 93:688-93.
5. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000, 83:65-9.
6. Mondorf W, Klinge J, Luban NL. Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. Haemophilia 2001, 7:13-9.
7. Klinge J, Auerswald G, Budde U. Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. Haemophilia 2001, 7:26-32.
8. Martin PG, Sukhu K, Chambers E, Giangrande PL. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 1999, 21:125-8.
9. Blanco AN, Peirano AA, Grosso SH, Gennari LC, Bianco RP, Lazzari MA. An ELISA system to detect anti-factor VIII antibodies without interference by lupus anticoagulants. Preliminary data in hemophilia A patients. Haematologica 2000, 85:1045-50.
10. Biggs R, Macfarlane RG. Human Blood Coagulation and its Disorders 1957, 2nd edn, Oxford, Blackwell Scientific Publications
11. Biggs R, Bidwell E. A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Br J Haematol 1959, 5:379-95.
12. Kasper C, Aledort L, Counts R. A more uniform measurement of factor VIII-inhibitors. Thromb Diath Haemorrh. 1975, 34:869-72.
13. Verbruggen B, Novakova I, Wessels H. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995, 73:247-51.
14. Giles AR, Verbruggen B, Rivard GE. A detailed comparison of the performance of the standard versus The Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb Haemost 1998, 79:872-5.
15. Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 2001, 86:1435-9.
16. Verbruggen HW, Novakova IR, Wessels JM, Verbeek K, Polenewen RJ. Frequency of inhibitors in haemophiliacs. Lancet 1992, 339:1301.
17. van Den Brink EN, Turenhout EA, Davies J. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood 2000, 95:558-63.
18. Lacroix-Desmazes S, Wootla B, Dasgupta S. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J Immunol 2006, 177:1355-63.
19. Mannucci PM, Tripodi A. Factor VIII clotting activity. Laboratory Techniques in Thrombosis. A Manual 1999, 107-13. 2nd revised edition of ECAT Assay Procedures, Dordrecht, the Netherlands, Kluwer Academic Publishers
20. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982, 60:1103-9.
21. Ling M, Duncan EM, Rodgers SE. Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. Br J Haematol 2001, 114:861-7.
22. Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002, 88:362-4.
23. Tripodi A, Mancuso ME, Chantarangkul V. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem 2005, 51:1883-5.
24. Favaloro EJ, Bonar R, Duncan E. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006, 96:73-8.
25. Favaloro EJ, Bonar R, Duncan E. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007, 39:504-11.
26. Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol 2003, 120:34-9.
27. Blanco AN, Cardozo MA, Candela M, Santarelli MT, Pérez Bianco R, Lazzari MA. Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients. Thromb Haemost 1997, 77:656-9.